Aptevo Therapeutics (APVO) Net Margin (2015 - 2022)
Aptevo Therapeutics (APVO) posted Net Margin of 5.72% for Q1 2022, down 35.54% sequentially from 8.87% in Q4 2021, and down 1138.0% YoY from 0.55% in Q1 2021.
Aptevo Therapeutics (APVO) Net Margin (2015 - 2022) Analysis & Trends
Aptevo Therapeutics has reported Net Margin for 8 years, with the latest figure at 5.72% in Q1 2022.
- Quarterly Net Margin fell 1138.0% year-over-year to 5.72% in Q1 2022, while the trailing twelve-month figure through Dec 2022 was 32.53% (up 2479.0% YoY) and the FY2022 annual result came in at 32.53%, up 2479.0% from the prior year.
- Net Margin declined to 5.72% in Q1 2022 per APVO's latest filing, from 8.87% in the prior quarter.
- Over five years, Net Margin peaked at 47.16% in Q3 2019 and troughed at 616.81% in Q4 2020.
- A 5-year average of 38.79% and a median of 3.41% in 2021 frame the typical range for Net Margin.
- The sharpest annual moves came in 2018 and 2021: Net Margin tumbled 90897 bps in 2018, then surged 62568 bps in 2021.
- Over 5 years, Net Margin stood at 0.62% in 2018, then surged by 1921 bps to 12.57% in 2019, then slumped by 5008 bps to 616.81% in 2020, then surged by 101 bps to 8.87% in 2021, then sank by 36 bps to 5.72% in 2022.
- According to Business Quant data, Net Margin over the past three periods registered 5.72%, 8.87%, and 2.58% for Q1 2022, Q4 2021, and Q3 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 12.74% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -3.12% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -16.51% |
| 10 | Aptevo Therapeutics | 3.30 Mn | -6.50 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 5.72% |
| Dec 31, 2021 | 8.87% |
| Sep 30, 2021 | 2.58% |
| Jun 30, 2021 | 4.24% |
| Mar 31, 2021 | 17.10% |
| Dec 31, 2020 | -616.81% |
| Sep 30, 2020 | 10.73% |
| Dec 31, 2019 | 12.57% |
| Sep 30, 2019 | 47.16% |
| Jun 30, 2019 | -33.86% |
| Mar 31, 2019 | -3.94% |
| Sep 30, 2018 | 0.62% |
| Jun 30, 2018 | 0.60% |
| Mar 31, 2018 | 1.33% |
| Sep 30, 2017 | 909.59% |
| Jun 30, 2017 | 84.46% |
| Mar 31, 2017 | 82.59% |
| Dec 31, 2016 | 26.39% |
| Sep 30, 2016 | 59.23% |
| Jun 30, 2016 | -126.37% |